Bedrijfsoverzicht
Seer, Inc. is a life sciences company dedicated to developing and commercializing products that decode the biology of the proteome to advance human health across major global markets including the United States, China, Australia, Europe, Israel, Japan, and South Africa. The enterprise operates within the healthcare sector, specifically functioning in the biotechnology industry, which focuses on the discovery, development, and commercialization of innovative medical products to address complex health challenges. The company currently maintains a market capitalization of $95.35M and employs a workforce of 124 individuals to execute its strategic initiatives. With an annual revenue of $16.58M, Seer, Inc. presents a profile typical of a mid-sized biotechnology entity, where the relatively modest market cap and revenue figures reflect the early-stage nature of the business and the capital-intensive requirements inherent in proteome research and product commercialization.
Financiële gezondheid
The company reported a revenue of $16.58M for the trailing twelve months, yet it recorded a net income of $-73,600,000 and an EBITDA of $-71,888,000, revealing a significant structural cost burden where operating expenses vastly exceed revenue generation. The free cash flow stands at $-27,648,000, indicating that the company is burning cash to fund research and development rather than generating liquidity for immediate distribution or debt repayment. Margin analysis shows a gross margin of 51.1%, which suggests that the cost of goods sold is managed reasonably well, contrasting sharply with an operating margin of -413.8% and a profit margin of 0.0% that highlight substantial overhead costs relative to sales. Despite the negative net income, the balance sheet holds $185.90M in cash against $23.65M in debt, supported by a debt-to-equity ratio of 9.12 which, while numerically high, is often characteristic of capital-intensive biotech firms relying on equity financing. The current ratio is 12.84, signaling an extremely strong liquidity position with current assets far exceeding current liabilities, providing ample short-term financial flexibility. Furthermore, the return on equity is -25.1% and the return on assets is -14.7%, metrics that indicate management is currently deploying capital to generate negative returns, a common phenomenon in growth-stage biotechnology companies that have not yet achieved commercial profitability.
Waarderingsbeoordeling
Valuation metrics for Seer, Inc. include a trailing P/E ratio that is not applicable due to negative earnings and a forward P/E of -1.61, a divergence that implies the market is pricing in future earnings recovery rather than current profitability. The price-to-book ratio is 0.37, suggesting that the stock trades at a significant discount to its book value, which may reflect market skepticism regarding the company's ability to monetize its intangible assets and research pipeline. Alternative valuation measures such as a price-to-sales ratio of 5.75 and an EV/EBITDA of 0.93 provide context for the company's valuation independent of earnings, showing a premium relative to sales that is typical for companies with high growth potential but unproven profitability. The stock price has fluctuated between a 52-week high of $2.41 and a 52-week low of $1.65, meaning the current price sits within this trading range, reflecting market volatility typical of small-cap biotechnology equities. The beta value is 1.60, indicating that the stock's price volatility is significantly higher than the broader market, exposing investors to greater swings in value in response to market movements and sector-specific news.
Growth & Income
Revenue growth for the year-over-year period is 5.0%, while earnings growth is not applicable due to the company's negative net income position, implying that top-line expansion is currently decoupled from bottom-line profitability. As a non-dividend payer, Seer, Inc. reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company retains all earnings to reinvest into research, development, and commercialization efforts rather than distributing cash to shareholders. This reinvestment strategy is standard for biotechnology firms in the development phase, where capital allocation prioritizes pipeline expansion over income generation for existing shareholders. The overall growth and income profile is defined by moderate revenue expansion coupled with significant cash consumption, resulting in a capital structure that relies on internal cash reserves and external financing to sustain operations until commercial products generate positive cash flows.